Promising human brain tumors therapy with interference RNA intervention (iRNAi)

Cancer Biology and Therapy

Volumn 9, Issue 5, 2010, Pages 397-407

  Rolle, Katarzyna ^a   Nowak, Stanislaw ^b   Wyszko, Eliza ^a   Nowak, Monika ^a   Zukiel, Ryszard ^b   Piestrzeniewicz, Rafal ^a   Gawronska, Iwona ^b   Barciszewska, Miroslawa Z ^b   Barciszewski, Jan ^b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Brain tumor; Glioblastoma multiforme; RNAi; Survival; TN C

Indexed keywords

DOUBLE STRANDED RNA; TENASCIN;

ADULT; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; OVERALL SURVIVAL; QUALITY OF LIFE; RNA INTERFERENCE; SEQUENCE HOMOLOGY;

EID: 77953700445     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.5.10958     Document Type: Article

References (37)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO Classification of tumors of the central nervous system. Acta Neuropathol 2007; 114:97-109.
2. Lévy P, Ripoche H, Laurendeau I, Lazar V, Ortonne N, Parfait B, et al. Microarray-based identification of tenascin C and tenascin X B, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007; 13:398-407.
3. Persson O, Krogh M, Saal LH, Englund E, Liu J, Parsons R, et al. Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol 2007; 85:11-24.
4. Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 2008; 6:21-30.
5. Quigley MR, Post C, Ehrlich G. Some speculation on the origin of glioblastoma. Neurosurg Rev 2007; 30:16-21.
6. Aghi M, Chiocca EA. Gene therapy for glioblastoma. Neurosurg Focus 20:18.
7. Sathornsumetee S, Rich J. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 2006; 6:1087-104.
8. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007; 282:18634-44.
9. Miller CR, Perry A. Glioblastoma. Morphologic and molecular genetic diversity. Arch Pathol Lab Med 2007; 131:397-406.
10. Pas J, Wyszko E, Rolle K, Rychlewski L, Nowak S, Zukiel R, et al. Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol 2006; 38:1594-602.
11. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007; 64:458-78.
12. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244:143-63.
13. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 2003; 100:15416-21.
14. Sarkar S, Nuttall RK, Liu S, Edwards DR, Yong VW. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 2006; 66:11771-80.
15. Bowers DC, Fan S, Walter KA, Abounader R, Rosen EM, Laterra J. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 2000; 60:4277-83. (Pubitemid 30636617)
16. Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol 2002; 12:12-20. (Pubitemid 33131358)
17. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, Demuth T, et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003; 116:4409-17.
18. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nature Rev Genet 2007; 8:173-84.
19. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778-809.
20. Wolters NM, Mackeigan JP. From sequence to function: using RNAi to elucidate mechanisms of human disease. Cell Death Differ 2008; 15:809-19.
21. Zukiel R, Nowak S, Wyszko E, Rolle K, Gawronska I, Barciszewska M, et al. Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther 2006; 5:1002-7.
22. Wyszko E, Rolle K, Nowak S, Zukiel R, Nowak S, Piestrzeniewicz R, et al. A multivariate analysis of patients with brain tumors treated with ATN-RNA. Acta Pol Pharm 2008; 65:677-84.
23. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity and guidelines. J Clin Oncology 1984; 2:187-93.
24. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15:774-80.
25. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection and survival. J Neurosurg 2001; 95:190-8.
26. Saxena A, Saxena SK, Shogen K. Effect of onconase on double-stranded RNA in vitro. Anticancer Res 2009; 29:1067-72.
27. Shi F, Gounko NV, Wang X, Ronken E, Hoekstra D. In situ entry of oligonucleotides into brain cells can occur through a nucleic acid channel. Oligonucleotides 2007; 17:122-33.
28. Bladergroen BA, Geelen MJ, Reddy AC, Declercq PE, Van Golde LM. Channelling of intermediates in the biosynthesis of phosphatidylcholine and phosphatidylethanolamine in mammalian cells. Biochem J 1998; 334:511-7.
29. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008; 19:111-24.
30. Stein P, Zeng F, Pan H, Schultz RM. Absence of nonspecific effects of RNA interference triggered by long double-stranded RNA in mouse oocytes. Dev Biol 2005; 286:464-71.
31. Gantier MP, Williams BR. The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev 2007; 18:363-71.
32. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5:834-9.
33. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003; 98:2430-9.
34. Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 2008; 6:21-30.
35. Barker FG, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42:709-20.
36. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, et al. Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori 2009; 95:317-24.
37. Medarova Z, Pham W, Kim Y, Dai G, Moore A. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer 2006; 118:2796-802.